Cochrane · systematic review · CD009768
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
Fisher, SA, Cutler, A, Doree, C, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 11.1%Ungraded 1 · 11.1%Very low 3 · 33.3%Low 4 · 44.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
MSCs compared to control/placebo for treating immune‐mediated inflammation post‐transplantation and in autoimmunity
Population: patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (prophylactic trials) (over duration of trial) MSCs vs control/placebo | HR 0.85 [0.5, 1.42] | 5 studies · 301 participants | Low Downgraded: risk of bias, imprecision |
All‐cause mortality (therapeutic trials) (over duration of trial) MSCs vs control/placebo | HR 1.12 [0.8, 1.56] | 1 study · 244 participants | Very low Downgraded: risk of bias |
Safety of MSC infusion MSCs vs control/placebo | no estimate extracted | 7 studies · 334 participants | Ungraded |
Health‐related quality of life MSCs vs control/placebo | no estimate extracted | NR | No studies |
Relapse of malignant disease (prophylactic trials) (>12‐month MSCs vs control/placebo | RR 1.08 [0.73, 1.59] | 6 studies · 323 participants | Low Downgraded: risk of bias, imprecision |
Incidence of acute GvHD (prophylactic trials) MSCs vs control/placebo | RR 0.86 [0.63, 1.17] | 6 studies · 247 participants | Low Downgraded: risk of bias, imprecision |
Incidence of chronic GvHD (prophylactic trials) MSCs vs control/placebo | RR 0.66 [0.49, 0.89] | 6 studies · 283 participants | Low Downgraded: risk of bias, imprecision |
Acute GvHD complete response (therapeutic trials) MSCs vs control/placebo | RR 1.16 [0.79, 1.7] | 1 study · 260 participants | Very low Downgraded: risk of bias |
Chronic GvHD complete response (therapeutic trials) MSCs vs control/placebo | RR 5 [0.75, 33.21] | 1 study · 40 participants | Very low Downgraded: risk of bias |